AFS Financial Group LLC Cuts Position in Pfizer Inc. (NYSE:PFE)

AFS Financial Group LLC decreased its position in Pfizer Inc. (NYSE:PFEFree Report) by 47.9% during the fourth quarter, Holdings Channel reports. The firm owned 21,320 shares of the biopharmaceutical company’s stock after selling 19,588 shares during the quarter. Pfizer comprises 0.6% of AFS Financial Group LLC’s portfolio, making the stock its 28th largest holding. AFS Financial Group LLC’s holdings in Pfizer were worth $614,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC raised its holdings in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after buying an additional 160,963,976 shares during the last quarter. Norges Bank acquired a new position in Pfizer during the fourth quarter worth about $3,150,472,000. Charles Schwab Investment Management Inc. grew its position in shares of Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares during the last quarter. Morgan Stanley grew its position in shares of Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after purchasing an additional 7,419,929 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Pfizer in the first quarter valued at approximately $311,238,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Truist Financial decreased their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 14th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $36.88.

Get Our Latest Research Report on PFE

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.15 during midday trading on Wednesday, hitting $27.40. The company’s stock had a trading volume of 11,148,622 shares, compared to its average volume of 42,872,313. Pfizer Inc. has a 1-year low of $25.61 and a 1-year high of $42.22. The firm’s fifty day moving average price is $27.41 and its 200-day moving average price is $29.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a market cap of $155.15 billion, a P/E ratio of 76.11, a P/E/G ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same period last year, the firm posted $1.14 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.